Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ji-Youn HanJin Soo Lee

Abstract

To determine whether uridine diphosphate-glucuronosyltransferase 1A1, UGT1A7, and UGT1A9 polymorphisms affect the pharmacokinetics (PK) of irinotecan and treatment outcome of Korean patients with advanced non-small-cell lung cancer (NSCLC). Eighty-one patients with advanced NSCLC were treated with irinotecan (80 mg/m2) on day 1 and 8 and cisplatin (60 mg/m2) on day 1 intravenously of each 3-week cycle. Genomic DNA was extracted from peripheral blood and genotyped using direct sequencing. We analyzed the association of UGT1A genotypes with irinotecan PK and clinical outcomes. All statistical tests were two-sided. In genotype-PK association analysis, UGT1A1*6/*6 (n = 6), UGT1A7*3/*3 (n = 6), and UGT1A9-118(dT)9/9 (n = 11) were associated with significantly lower area under the time-concentration curve (AUC) SN-38G to SN-38 (AUC(SN-38G)/AUC(SN-38)) ratio (P = .002, P = .009, and P = .001, respectively). In linkage disequilibrium analysis, the UGT1A7 variants were highly linked with the UGT1A1*6 (D' = 0.85, r2 = 0.63) and UGT1A9*22 (D' = 0.95, r2 = 0.88), which was substantiated in haplotype analysis. Patients with UGT1A1*6/*6 had lower tumor response and higher incidence of severe neutropenia. UGT1A9-118(dT)9/9 also showed a trend...Continue Reading

References

Nov 1, 1988·Genetics·R C Lewontin
Nov 1, 1968·Genetics·W G Hill, A Robertson
Nov 2, 1995·The New England Journal of Medicine·P J BosmaR P Oude Elferink
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E GuptaM J Ratain
Aug 11, 1998·Journal of Chromatography. B, Biomedical Sciences and Applications·A SparreboomK Nooter
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F DeVoreL L Miller
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Jul 14, 2001·The New England Journal of Medicine·D J SargentR L Schilsky
Sep 18, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L RothenbergS Wadler
Sep 20, 2001·Journal of the National Cancer Institute·Z ZhengP Lazarus
Jan 5, 2002·Drug Metabolism Reviews·M B FisherS A Wrighton
May 7, 2002·The Pharmacogenomics Journal·L IyerM J Ratain
Feb 6, 2003·British Journal of Cancer·S NegoroUNKNOWN CPT-11 Lung Cancer Study Group West
Feb 7, 2003·Current Medicinal Chemistry·M K Ma, H L McLeod
Mar 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico InnocentiMark J Ratain
Apr 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yue WangMasao Omata
Jun 5, 2004·Clinical Pharmacology and Therapeutics·Federico Innocenti, Mark J Ratain
Jul 15, 2004·European Journal of Human Genetics : EJHG·Pierre-Antoine GourraudAnne Cambon-Thomsen
Aug 3, 2004·Journal of Clinical Pharmacology·Luca PaoluzziAlex Sparreboom
May 3, 2005·Pharmacogenetics and Genomics·Federico InnocentiMark J Ratain
Mar 1, 1982·TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·D E Rowe
Jul 1, 1990·Evolution; International Journal of Organic Evolution·D Charlesworth, B Charlesworth

❮ Previous
Next ❯

Citations

Nov 10, 2007·Cancer Chemotherapy and Pharmacology·Kimie SaiJun-ichi Sawada
Feb 18, 2009·Cancer Chemotherapy and Pharmacology·Myung Hee ChangKeunchil Park
May 6, 2009·Cancer Chemotherapy and Pharmacology·Crystal S DenlingerPeter J O'Dwyer
Nov 23, 2006·World Journal of Urology·Peter C BlackColin P Dinney
Apr 25, 2009·International Journal of Clinical Oncology·Masahide OnoueKen-ichi Inui
May 29, 2012·International Journal of Clinical Oncology·Tetsuya SasakiYasutsuna Sasaki
Jul 6, 2013·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Hiroko OtsukaKazuo Shirouzu
May 17, 2013·Clinical Pharmacokinetics·Ying ChenYazdi K Pithavala
Aug 22, 2009·Journal of Human Genetics·Pei-Chieng ChaYusuke Nakamura
Jul 20, 2007·Assay and Drug Development Technologies·O V TrubetskoyV S Trubetskoy
Sep 24, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S R ParkN K Kim
Oct 23, 2010·Japanese Journal of Clinical Oncology·Keishi YamashitaYasutsuna Sasaki
Jan 31, 2008·Journal of the National Cancer Institute·Wataru IchikawaYasutsuna Sasaki
Sep 23, 2009·Anti-cancer Drugs·Christoph SchulzHans-Joachim Stemmler
May 5, 2012·Pharmacogenetics and Genomics·Sung Kweon ChoJae Yong Chung
Apr 2, 2008·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Kimie SaiHironobu Minami
Feb 8, 2011·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Yoshiro Saito
Jun 6, 2013·PloS One·Ji Won LeeHyo Seop Ahn
Jun 11, 2011·The Oncologist·Maarten J DeenenJan H M Schellens
Sep 26, 2012·Drug Metabolism and Pharmacokinetics·Eun Sil OhJae-Yong Chung
Sep 19, 2012·Drug Metabolism and Pharmacokinetics·Jason A SprowlAlex Sparreboom
Jan 1, 2011·Pharmacogenomics and Personalized Medicine·Jing Li, Martin H Bluth
Mar 20, 2010·Pharmacogenomics·Yutaka Fujiwara, Hironobu Minami

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.